BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Devaux M, Gerard L, Richard C, Bengrine-Lefevre L, Vincent J, Schmitt A, Ghiringhelli F. Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. World J Clin Oncol 2019; 10(2): 75-85 [PMID: 30815374 DOI: 10.5306/wjco.v10.i2.75]
URL: https://www.wjgnet.com/2218-4333/full/v10/i2/75.htm
Number Citing Articles
1
Kei Muro, Taylor Salinardi, Arvind Rup Singh, Teresa Macarulla. Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World DataCancers 2020; 12(4): 844 doi: 10.3390/cancers12040844
2
Tomas Buchler, Igor Kiss, Jana Hornova, Ondrej Fiala, Marketa Wiesnerova, Michal Svoboda, Jiri Silar, Katerina Kopeckova, Alexandr Poprach, Jindrich Finek, Lubos Petruzelka, Bohuslav Melichar. Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical PracticeTargeted Oncology 2020; 15(2): 193 doi: 10.1007/s11523-020-00705-1
3
Eleonora Lai, Stefano Cascinu, Mario Scartozzi. Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical PracticeFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.637823
4
Raquel Claramunt García, Carmen Lucía Muñoz Cid, Andrés Sánchez Ruiz, Juan Francisco Marín Pozo. Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experienceEuropean Journal of Clinical Pharmacology 2022; 78(2): 287 doi: 10.1007/s00228-021-03235-5
5
Pu Ge, Abudurosuli Reyila, Xin‐yi Li, Si‐yu Liu, Yi‐xuan Jiang, Ya‐jie Yang, Xia‐lei Li, Ying Bian. Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: A systematic review and PRISMA‐Compliant single‐arm Meta‐Analysis of noncomparative clinical studies and randomized controlled trialsJournal of Clinical Pharmacy and Therapeutics 2022; 47(6): 798 doi: 10.1111/jcpt.13610